<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":3393,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Streck, Inc. v. Research & Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed. Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/4e497939ce7d90f53679c7e8161db722'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/4e497939ce7d90f53679c7e8161db722'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GV4AQ003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1GV4AQ003">Previous Result: <span>Walling v. Everett, Civil Action No. 11-...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GV4B8003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1GV4B8003">Next Result: <span>Loya v. Sebelius, 840 F. Supp. 2d 245, 2...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation distinguished" title="Distinguished"></div>
<div class='title left' title='Streck, Inc. v. Research &amp; Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed. Cir. 2012), Court Opinion'>
Streck, Inc. v. Research &amp; Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed....
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Streck, Inc. v. Research & Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed. Cir. 2012), Court Opinion</div>
<div class='docId'>X1GURL4003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Streck, Inc. v. Research & Diagnostic Sys., Inc.</div>
<div class='displayCitation'>101 U.S.P.Q.2d 1225</div>
<div class='displayCitation'>2012 BL 5365</div>
<div class='displayCitation'>665 F.3d 1269</div>
<div class='displayCitation'>bna a0d0h0z4a6</div>
<div class='displayCitation'>bna a0d0h6c7f7</div>
<div class='displayCitation'>wkffecase:25671506</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1GURL4003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Streck, Inc. v. Research &amp; Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed. Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Streck, Inc. v. Research &amp; Diagnostic Sys., Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GURL4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1GURL4003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1GURL4003" /><input id="title" name="title" type="hidden" value="Streck, Inc. v. Research &amp; Diagnostic Sys., Inc., 665 F.3d 1269, 101 U.S.P.Q.2d 1225 (Fed. Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="DISTINGUISHED" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="4e497939ce7d90f53679c7e8161db722" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1GURL4003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="true" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%34e%34%39%37%39%33%39ce%37d%39%30f%35%33%36%37%39c%37e%38%31%36%31db%37%32%32%2Fdocument%2FX%31GURL%34%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/bcite/X1GURL4003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/bcite/X1GURL4003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/bcite/X1GURL4003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/related_content/X1GURL4003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1682407817219";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,ReporterOfDecisions,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">665 F.3d 1269</div>
<div class="cite" data-cite-type="ReporterOfDecisions">101 U.S.P.Q.2d 1225</div>
<div class="cite" data-cite-type="DocketNumber">2011-1044</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 5365</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">U.S.P.Q.2d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">***</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Federal Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
STRECK, INC., Plaintiff-Appellee, v. RESEARCH &amp; DIAGNOSTIC SYSTEMS,
INC. and Techne Corporation, Defendants-Appellants.
</center></p>
<hr align="center" width="65%">
<p><center>
No. 2011-1044.
</center></p>
<p><center>
January 10, 2012.
<span CLASS="page_no" data-cite="101 uspq 2d 1226" data-cite-type="ReporterOfDecisions" data-cite-pageno="1226" data-primary-citation="101 U.S.P.Q.2d 1225">[**1226]</span> </center></p>
<div class="headnotesToggle clearfix"><button id="toggle_headnotes_button" class="bootstrap skinButton sourceButton wide right hideSource" data-target="#headnotes_container"><span>Hide Headnotes</span></button></div>
<div class="headnotesContainer" id="headnotes_container">
<div class="headnotesContainerTitle">BNA Headnotes</div>
<div class="headnoteTitle"><a href="http://www.bloomberglaw.com/document/1475619602000128">U.S. Patents Quarterly</a></div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>[1]</span> <span>Jurisdiction &mdash; Subject matter jurisdiction &mdash;
Case or controversy </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=405.0703" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="405.0703">&#9658;405.0703</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_1" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_1" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Burden of proof </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.35" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.35">&#9658;410.35</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_2" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_2" class="headnoteContent"></div>
<div class="headnote_text">
Existence of case or controversy in patent suit must be evaluated on claim-by-claim basis, and if particular claims are withdrawn or otherwise not asserted by plaintiff, counterclaimant must show existence of continuing case or controversy with respect to those claims; in present case, federal district court lacked jurisdiction over unasserted claims, and its decision not to address them is affirmed, since plaintiff patentee narrowed scope of asserted claims at start of litigation pursuant to local patent rules, and further narrowed scope of its claims before any dispositive rulings by district court, and since both parties were on notice from start of litigation that scope of claims at issue were only subset of full patents in suit, and parties knew precisely which claims were at issue well before court ruled on parties' summary judgment motions or conducted trial.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">PATENTS</div>
<div class="headnoteDescriptor">
<span>[2]</span> <span>Patentability/Validity &mdash; Specification &mdash; Written description </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1103" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1103">&#9658;115.1103</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_3" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_3" class="headnoteContent"></div>
<div class="headnote_text">
Patents in suit, directed to &ldquo;integrated&rdquo; reticulocyte controls for checking accuracy of instruments used for testing blood samples, provide adequate written description for claimed integrated controls using either &ldquo;true&rdquo; reticulocytes or reticulocyte analogs, since inventor identified language in patents providing that &ldquo;the reticulocyte component may comprise true mammalian reticulocytes&rdquo;
prepared by red blood cell encapsulation or by isolation from whole blood, since inventor testified that one patent specifically &ldquo;covers both kinds&rdquo; of reticulocytes, since mere fact that inventor chose to reduce invention to practice using reticulocyte analog rather than true reticulocyte is not relevant to written description inquiry, since specifications of patents in suit refer to several types of true reticulocytes, since analogs are designed to mimic true reticulocytes, and use of true reticulocytes in &ldquo;stand-alone&rdquo; controls was well-known in prior art, and since, therefore, person of ordinary skill in art would have recognized that claimed integrated controls could be made using either true reticulocytes or reticulocyte analogs.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteDescriptor">
<span>[3]</span> <span>Patentability/Validity &mdash; Specification &mdash; Enablement </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=115.1105" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="115.1105">&#9658;115.1105</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_4" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_4" class="headnoteContent"></div>
<div class="headnote_text">
Rule that patentee broadly claiming two distinct species must enable both of them does not apply in present case, and patents in suit, directed to &ldquo;integrated&rdquo; reticulocyte controls for checking accuracy of instruments used for testing blood samples, enable claimed integrated hematology controls using &ldquo;true&rdquo; reticulocytes as well as reticulocyte analogs, since there is unrebutted evidence in record that true reticulocytes and reticulocyte analogs work in exactly same way in hematology control, that they are virtually indistinguishable, even to person of skill in art, and that enabling disclosure in patents for use of reticulocyte analogs thus is equally enabling with respect to true reticulocytes, and since testimony of patentee's experts, taken in context, establishes that no undue experimentation would be required to create integrated control using true reticulocytes once teachings of patents in suit were known.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">JUDICIAL PRACTICE AND PROCEDURE</div>
<div class="headnoteDescriptor">
<span>[4]</span> <span>Procedure &mdash; Prior adjudication &mdash; Res judicata;
collateral estoppel </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.1503" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.1503">&#9658;410.1503</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_5" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_5" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; New trial; JMOL </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.30" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.30">&#9658;410.30</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_6" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_6" class="headnoteContent"></div>
<div class="headnoteDescriptor">
<span>Procedure &mdash; Burden of proof </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=410.35" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="410.35">&#9658;410.35</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_7" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_7" class="headnoteContent"></div>
<div class="headnote_text">
Denial of defendants' motion for judgment as matter of law on issue of priority of invention in patent infringement action is affirmed, since priority issues in present case are controlled by prior decision in related action brought under 35 U.S.C. &sect;146, in which award of priority to plaintiff was affirmed, since defendants' failure to establish priority by preponderance of evidence in Section 146 action necessarily means that they could not show priority under clear-and-convincing burden required in present infringement action, since jury's verdict for plaintiff on priority issue in this case is entitled to substantial deference, and since related appeal involved same parties, evidence, and priority issue presented in instant appeal, and defendants are therefore barred by doctrine of collateral estoppel from challenging earlier priority determination; resolution of that appeal also renders moot defendants'
arguments regarding presentation of evidence on priority issue.</div>
</div>
<div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="headnote">
<div class="headnoteSlug">REMEDIES</div>
<div class="headnoteDescriptor">
<span>[5]</span> <span>Non-monetary and injunctive &mdash; Equitable relief &mdash;
Permanent injunctions &mdash; Patents </span> <a href="http://www.bloomberglaw.com/document/1682407817219/class_outline_search?source_id=105.455998&amp;search_service_code=pq2co-ref&amp;search_node_id=505.0709.07" rel="ref" data-source-id="105.455998" data-service-code="pq2co-ref" data-node-id="505.0709.07">&#9658;505.0709.07</a> <span class="headnoteToggle">[<a href="#headnote_content_pq2coref_8" data-source-id="105.455998" class="toggle">Show Topic Path</a>]</span>
</div>
<div id="headnote_content_pq2coref_8" class="headnoteContent"></div>
<div class="headnote_text">
Permanent injunction entered in infringement action is not overbroad, since language of order identifies specific accused products at issue in case, and mere inclusion of language prohibiting defendants &ldquo;from otherwise infringing the asserted claims&rdquo; of patents in suit, when viewed in context of entire order and record on which it was entered, does not render injunction overbroad.</div>
</div>
</div>
<script type="text/javascript">
					jQuery(function($) {
						$('#toggle_headnotes_button').click(document_toggleHeadnoteVisibility);
					});
				</script><div id="para2" printdualcolumn="true"><p>
  Appeal from the United States District Court for the
District of Nebraska, Joseph F. Bataillon, Chief Judge.
</p></div>
<span CLASS="page_no" data-cite="665 f 3d 1270" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1270" data-primary-citation="665 F.3d 1269">[*1270]</span> <div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="665 f 3d 1271" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1271" data-primary-citation="665 F.3d 1269">[*1271]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="665 f 3d 1272" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1272" data-primary-citation="665 F.3d 1269">[*1272]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
[EDITORS' NOTE:  THIS PAGE CONTAINS HEADNOTES. HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
<span CLASS="page_no" data-cite="665 f 3d 1273" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1273" data-primary-citation="665 F.3d 1269">[*1273]</span> 
</p></div>
</div>
<div id="para2" printdualcolumn="true"><p>
  Floyd R. Nation, Winston &amp; Strawn LLP, of Houston, TX,
argued for plaintiff-appellee. With him on the brief was
Merritt D. Westcott. Of counsel on the brief was Richard L.
Stanley, of Houston, TX.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Kurt J. Niederluecke, Fredrikson &amp; Byron, P.A., of
Minneapolis, MN, argued for defendants-appellants. With him on
the brief was Grant D. Fairbairn. Of counsel on the brief was
Martin M. Zoltick, Rothwell, Figg, Ernst &amp; Manbeck, of
Washington, DC.
</p></div>
<div id="para2" printdualcolumn="true"><p>
  Before NEWMAN, O'MALLEY, and REYNA, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  O'MALLEY, Circuit Judge.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In this patent case, Streck, Inc. ("Streck") filed suit
against Research &amp; Diagnostic Systems, Inc. and Techne
Corporation (collectively, "R &amp; D") in the United States
District Court for the District of Nebraska alleging that R
&amp; D infringed three of Streck's patents for hematology
control technology: <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">U.S. Patent Nos. 6,200,500</a> ("the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500
Patent</a>"), <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">6,221,-668</a> ("the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a>"), and <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">6,399,388</a>
("the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patent</a>") (collectively, "the
patents-in-suit"). R&amp; D counterclaimed for declaratory
judgment of noninfringement and invalidity.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R&amp; D appeals from the district court's: (1) dismissal of R
&amp; D's invalidity counter-claims with respect to claims
Streck did not include in its infringement allegations (the
"unasserted claims"); (2) denial of summary judgment for R
&amp; D and grant
<span CLASS="page_no" data-cite="665 f 3d 1274" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1274" data-primary-citation="665 F.3d 1269">[*1274]</span> 
of summary judgment for Streck on written description; (3)
denial of judgment as a matter of law ("JMOL") for R &amp; D
and grant of JMOL for Streck on enablement; (4) denial of R
&amp; D's renewed motion for JMOL and motion for a new trial on
priority; and (5) issuance of a permanent injunction.
<i>Streck, Inc. v. Research &amp; Diagnostic Sys., Inc.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d 988</a> (D.Neb. 2009) ("<i>Summary Judgment Order");</i>
<i>Streck, Inc. v. Research &amp; Diagnostic Sys., Inc.</i>,
No. <cite>8:06cv458</cite>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 WL 3926059, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 U.S. Dist. LEXIS 104461
(D.Neb. Sept. 30, 2010) ("<i>Denial of Renewed JMOL</i>
<i>Order</i>"). Because we conclude that the district court did
not err in refusing to address the validity of the unasserted
claims and correctly denied R &amp; D's written description and
enablement defenses as a matter of law, and <span CLASS="page_no" data-cite="101 uspq 2d 1227" data-cite-type="ReporterOfDecisions" data-cite-pageno="1227" data-primary-citation="101 U.S.P.Q.2d 1225">[**1227]</span> because the issue
of priority is controlled by this court's resolution in Appeal
No. <cite>2011-1045</cite>,<a HREF="#fn100" name="fnref_fn100">[fn1]</a> we affirm the district court's judgment
against R&amp; D and its decision granting a permanent
injunction in favor of Streck.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               BACKGROUND
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                          A. Factual Background
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The technology involved in this case relates to hematology
controls. These controls are used to monitor and test the
accuracy and consistency of hematology analyzers, which
clinical laboratories use to analyze patient blood samples.
Specifically, hematology analyzers measure the <span CLASS="page_no" data-cite="2012 bl 5365 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[***2]</span> various
components of whole blood, including red blood cells, white
blood cells, platelets, and reticulocytes,<a HREF="#fn200" name="fnref_fn200">[fn2]</a> and the
information gathered is used to diagnose and treat diseases.
Both Streck and R&amp; D manufacture and sell hematology
control products.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prior to 1996, hematology instruments measured reticulocytes
and white blood cells separately and thus required separate
stand-alone hematology controls &mdash; i.e., those that
measured only a single component of blood. Stand-alone controls
using true reticulocytes<a HREF="#fn300" name="fnref_fn300">[fn3]</a> and reticulocyte analogs were
well-known in the art before the applications that matured into
the patents-in-suit were filed. Dr. Alan Johnson, a senior
scientist at R &amp; D, is a named co-inventor on <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2HOCC400GJ?jcsearch=usp%205736402&amp;summary=yes#jcite">U.S. Patent
No. 5,736,402</a> ("the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2HOCC400GJ?jcsearch=usp%205736402&amp;summary=yes#jcite">402 Patent</a>"), which claims
stand-alone true reticulocyte controls. In the mid-1990s, Dr.
Wayne Ryan, the majority owner and Chief Executive Officer of
Streck, invented and patented a method for making reticulocyte
analogs and using those analogs in a stand-alone control.
<i>See</i> <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">U.S. Patent No. 5,432,089</a> ("the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089
Patent</a>"). The &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089 Patent</a> explains that reticulocyte
analogs "exhibit a reticulocyte continuum and distribution that
is similar to that of normal human reticulocytes." &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089
Patent</a> col.8 11.36-39.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Hematology instrument manufacturers began developing a
hematology analyzer that could measure both reticulocytes and
white blood cells simultaneously in the same blood sample.
Accordingly, there was a need for an integrated hematology
control containing at least: (1) a stabilized reticulocyte
component; and (2) a fixed and stabilized white blood cell
component.
<span CLASS="page_no" data-cite="665 f 3d 1275" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1275" data-primary-citation="665 F.3d 1269">[*1275]</span> 
Over time, both R&amp; D and Streck began working on
projects aimed at developing an integrated hematology control.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On August 20, 1999, Streck filed a patent application directed
to an integrated reticulocyte control. That application became
the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>, which issued on March 31, 2001. Ryan is
the named inventor on the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>. The &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668
Patent</a>, which issued on April 24, 2001, and the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388
Patent</a>, which issued on June 4, 2002, are continuations of the
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>. Ryan and John Scholl, Streck's research and
development manager, are named as coinventors on the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668</a>
and &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patents</a>. Both Ryan and Scholl assigned their
rights in the patents to Streck.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The parties agree that Claim 1 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> is
representative for this appeal. It claims "[a] hematology
control composition comprising: a) a stabilized reticulocyte
component; and b) a fixed and stabilized white blood cell
component capable of exhibiting a five-part differential."
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> col.16 ll.41-45. The specification explains
that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  the control may suitably contain stabilized
  reticulocytes (that is, immature anucleate red blood
  cells containing some ribonucleic acid) or an analog
  thereof. For example, among possible embodiments, the
  reticulocyte component may comprise true mammalian
  reticulocytes prepared for instance by mammalian (e.g.
  human) red blood cell encapsulation or by isolation
  from whole blood. The reticulocyte component is
  prepared in any suitable manner. <i>See, e.g.</i>,
  [the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089 Patent</a>]. Alternatively, it is possible
  to obtain suitable reticulocytes by obtaining blood
  from an anemic animal (e.g., a pig, goat, rabbit or
  the like).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> col.3 11.14-25. The district court construed
the patents-<span CLASS="page_no" data-cite="2012 bl 5365 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[***3]</span> in-suit to encompass an integrated reticulocyte
control using either true reticulocytes or reticulocyte
analogs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 18, 1999, roughly two months after Streck filed its
application, R &amp; D filed its own patent application
relating to integrated reticulocyte controls. Dr. Johnson is
the named inventor of the control composition in R &amp; D's
application. In 2003, after some of Streck's patents had
issued, R&amp; D copied claims from Streck's patents into its
still-pending application and asked the United <span CLASS="page_no" data-cite="101 uspq 2d 1228" data-cite-type="ReporterOfDecisions" data-cite-pageno="1228" data-primary-citation="101 U.S.P.Q.2d 1225">[**1228]</span> States Patent
and Trademark Office ("the PTO") to declare an interference to
determine priority of invention. Facts relating to the parties'
priority dispute are set forth in companion Appeal
No. <cite>2011-1045</cite>, which was previously decided by this court. To
the extent necessary, those facts are incorporated by reference
herein.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While R &amp; D's interference request was pending, R&amp; D
began manufacturing and selling integrated hematology controls,
the first of which was referred to as CBC-XE. R&amp; D
subsequently began producing controls under the names CBC-4K
Plus Retics and CBC-5D Plus Retics as well. It is undisputed
that Ryan used his reticulocyte analog as the reticulocyte
component of the integrated control when he reduced his
invention to practice. In contrast, R &amp; D's integrated
controls use true reticulocytes as the reticulocyte component.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                          B. Procedural History
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On June 29, 2006, Streck filed suit against R &amp; D in the
District of Nebraska alleging willful infringement of the
patents-in-suit. R&amp; D counterclaimed seeking a declaration
that the asserted claims of the patents-in-suit are invalid and
not infringed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
1. Identification of the Asserted Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On December 14, 2006, the parties agreed to be bound by the
Patent Local
<span CLASS="page_no" data-cite="665 f 3d 1276" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1276" data-primary-citation="665 F.3d 1269">[*1276]</span> 
Rules of the United States District Court for the Northern
District of California. <i>Summary Judgment Order</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 993</a>. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X11FGCO003?jcsearch=CALRDCNO%20Patent%20L.R.%203-1&amp;summary=yes#jcite">Patent Local Rule 3-1</a> requires that, "[n]ot
later than 10 days after the Initial Case Management
Conference, a party claiming patent infringement shall serve on
all parties a `Disclosure of Asserted Claims and Preliminary
Infringement Contentions'" which sets forth, among other
things, "[e]ach claim of each patent in suit that is allegedly
infringed by each opposing party." <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X11FGCO003?jcsearch=CALRDCNO%20Patent%20L.R.%203-1&amp;summary=yes#jcite">N.D. Cal. Patent L.R.
3-1</a>(a).<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Likewise, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X11FGCS003?jcsearch=CALRDCNO%20Patent%20L.R.%203-3&amp;summary=yes#jcite">Rule 3-3</a> provides that "[n]ot later than
45 days after service upon it of the `Disclosure of Asserted
Claims and Infringement Contentions,' each party opposing a
claim of patent infringement, shall serve on all parties its
`Invalidity Contentions'" identifying each item of prior
art that allegedly anticipates a claim or renders it obvious.
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X11FGCS003?jcsearch=CALRDCNO%20Patent%20L.R.%203-3&amp;summary=yes#jcite">Patent L.R. 3-3(a)</a>. The parties agreed that, consistent with
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X11FGD4003?jcsearch=CALRDCNO%20Patent%20L.R.%203-7&amp;summary=yes#jcite">Rule 3-7</a>, supplementation of invalidity contentions "was
allowed only by order of [the] court on a showing of good
cause." <i>Summary Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 994</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pursuant to the Patent Local Rules, in a document dated
December 15, 2006, Streck provided its "Disclosure of Asserted
Claims and Preliminary Infringement Contentions," which
identified the following "claims asserted to be infringed":
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R&amp; D directly infringes, induces others to
  infringe, and/or contributes to third-party
  infringement of at least claims 28 and <span CLASS="page_no" data-cite="2012 bl 5365 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[***4]</span> 29 of the
  &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 patent</a>, claims 1, 4, 5, 6, 8-9, 13, 15, and
  26-29 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 patent</a>, and claim 13 of the
  &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 patent</a> literally and/or under the doctrine
  of equivalents through the manufacture, use, sale,
  offer to sell (including R &amp; D's related promotion
  and advertising), and/or importation of R &amp; D's
  hematology controls designated "CBC-XE" and "CBC-4K
  Plus Retics."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Streck, Inc. v. Research &amp; Diagnostic Sys., Inc.</i>,
No. <cite>8:06cv458</cite> (D.Neb. Apr. 16, 2007), ECF No. 32-4 at 2-3. In
response, on January 19, 2007, R &amp; D submitted its
"Preliminary Invalidity Contentions" stating that the "Johnson
Inventions anticipate each claim asserted by Streck, including
at least claims 28 and 29 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 patent</a>, claims 1,
4, 5, 6, 8-9, 13, 15, and 26-29 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 patent</a>, and
claim 13 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 patent</a>." <i><cite>Id</cite>.</i> ECF No. 32-5
at 3. On December 16, 2008, Streck informed R&amp; D that it
was asserting only the following ten claims: Claims 28-29 of
the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>; Claims 1, 4, 5, 6, 8, 9, and 13 of the
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a>; and Claim 13 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patent</a>.
<i>Summary Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 994</a>.
Subsequently, in March 2008, R &amp; D amended its invalidity
contentions to assert that all claims of the patents-in-suit,
except Claim 20 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patent</a>, were invalid for
failure to satisfy enablement and written description
requirements.<a HREF="#fn500" name="fnref_fn500">[fn5]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
         2. Claim Construction and Final Invalidity Contentions
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On June 5, 2008, the district court conducted a hearing
pursuant to <i>Markman v. Westview Instruments, Inc.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5CCQ2?jcsearch=517%20us%20370&amp;summary=yes#jcite">517 U.S. 370</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5CCQ2?jcsearch=517%20us%20370&amp;summary=yes#jcite">372</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5CCQ2?jcsearch=116%20supreme%20court%201384&amp;summary=yes#jcite">116 S.Ct. 1384</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5CCQ2?jcsearch=134%20l%20ed%202d%20577&amp;summary=yes#jcite">134 L.Ed.2d 577</a> (1996). The
court issued <span CLASS="page_no" data-cite="101 uspq 2d 1229" data-cite-type="ReporterOfDecisions" data-cite-pageno="1229" data-primary-citation="101 U.S.P.Q.2d 1225">[**1229]</span> its claim construction order on November 12, 2008.
In that order, the court noted that the "claims of the patents
make it clear that the reticulocyte
<span CLASS="page_no" data-cite="665 f 3d 1277" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1277" data-primary-citation="665 F.3d 1269">[*1277]</span> 
component of the control composition can be either a
reticulocyte or an analog of a reticulocyte." <i>Claim</i>
<i>Construction Order</i>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">2008 BL 253491</a>], 2008 WL 4891132, at *8,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">2008 BL 253491</a>], 2008 U.S. Dist. LEXIS 91865, at *23. The court construed "reticulocyte
analog" to mean "particles made from a source other than
naturally occurring reticulocytes, such particles appearing to
the instrument as reticulocytes that naturally occur in the
whole blood for which the instrument is intended." <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">Id.
at *11</a>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">2008 BL 253491</a>], 2008 U.S. Dist. LEXIS 91865, at *33.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On January 2, 2009, R&amp; D served its final set of invalidity
contentions alleging that: (1) Johnson's inventions anticipated
each of Streck's asserted claims; (2) each claim of the
patents-in-suit, except Claim 20 of the &prime;388 Patent, was
invalid for failure to satisfy enablement and written
description requirements; and (3) Claim 3 of both the
&prime;500 and the &prime;668 Patents was invalid for
indefiniteness. <i>See Summary Judgment Order</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 994</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                       3. Summary Judgment Motions
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On March 27, 2009, the parties filed cross-motions for summary
judgment. Streck's motion requested judgment that: (1) its
asserted claims were valid and contained sufficient written
description; and (2) R &amp; D had infringed the asserted
claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D's motion asserted that: (1) Claim 3 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500</a>
and &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patents</a> was invalid as indefinite, inoperative,
or not enabled; (2) all claims of the patents-in-suit (except
Claim 20 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patent</a>) were invalid for lack of
written description and lack of enablement; (3) the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388
Patent</a> was invalid for misjoinder<a HREF="#fn600" name="fnref_fn600">[fn6]</a>; and (4) there was no
evidence to support a finding of willful infringement.
Specifically, with respect to invalidity, R&amp; D argued that
the patents-in-suit described an integrated control with
reticulocyte <i>analogs</i> and did not adequately describe
an integrated control with true, naturally occurring
reticulocytes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On September <span CLASS="page_no" data-cite="2012 bl 5365 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[***5]</span> 9, 2009, the district court denied R &amp; D's
motion for summary judgment on its written description defense
and granted Streck's cross-motion. First, the court held that,
as a matter of law, Streck's patents adequately described an
integrated control with true reticulocytes. <i>Summary</i>
<i>Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 999</a>. The court noted that
R &amp; D's arguments focused primarily on enablement, rather
than written description, and that R&amp; D relied heavily on
Claim 3 of &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>, which was not asserted in
Streck's initial disclosures. <i><cite>Id</cite>.</i> The court further
found that the level of skill in the art was high, and that a
person of such skill would understand that the patents were
meant to encompass both natural and analog reticulocytes. The
court denied R &amp; D's motion for summary judgment on
enablement, finding that "there is a genuine issue of material
fact with respect to the enablement issue." <i></i><cite>Id.
at 999-1000</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Next, the court dismissed R &amp; D's invalidity counterclaims
with respect to Claim 3 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500</a> and &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668
Patents</a>. The court found that Streck did not assert
infringement of those claims, and that R&amp; D had "no
`reasonable apprehension' it will face an infringement suit on
any claims other than those that Streck asserts it has
in-fringed in this action." <i></i><cite>Id. at 1000</cite>. Finally, the
court found that R&amp; D had, as a matter of law, literally
infringed the claims at issue, and that there was evidence from
<span CLASS="page_no" data-cite="665 f 3d 1278" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1278" data-primary-citation="665 F.3d 1269">[*1278]</span> 
which a jury could find willfulness.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> <i><cite>Id</cite>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                          4. Motions <i>in Limine</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On September 4, 2009, both parties filed motions <i>in</i>
<i>limine.</i> R&amp; D sought, among other things, to exclude
evidence relating to Streck's conception prior to 1997, on
grounds that conception is irrelevant to the question of the
priority of invention. Streck sought to exclude any evidence
challenging the validity of the seventy-four unasserted claims
of the patents-in-suit. Streck explained that it had informed R
&amp; D that it was only asserting infringement with respect to
nine out of the total eighty-three claims of the patents-in-suit
and that R &amp; D should be prohibited from presenting
evidence or testimony relating to the seventy-four unasserted
claims.<a HREF="#fn800" name="fnref_fn800">[fn8]</a> On October 15, 2009, the district court denied R
&amp; D's motion, <span CLASS="page_no" data-cite="101 uspq 2d 1230" data-cite-type="ReporterOfDecisions" data-cite-pageno="1230" data-primary-citation="101 U.S.P.Q.2d 1225">[**1230]</span> without prejudice to reassertion at trial, on
grounds that it "involve[d] the weight rather than the
admissibility of the evidence." <i>Streck, Inc. v. Research</i>
<i>&amp; Diagnostic Sys., Inc.</i>, No. 8:06cv458,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BVROA003?jcsearch=2009%20BL%20222357&amp;summary=yes#jcite">2009 BL 222357</a>], 2009 WL 3335924, at *3-l, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BVROA003?jcsearch=2009%20BL%20222357&amp;summary=yes#jcite">2009 BL 222357</a>], 2009 U.S. Dist. LEXIS 96196, at *9
(D.Neb. Oct. 15, 2009). The court also denied Streck's motion:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although the court finds the subject of the motion is
  more properly viewed as an objection to be raised at
  trial, the court notes it will generally sustain such
  an objection. . . . The validity of claims other than
  those alleged to have been infringed is not an issue
  in this case and evidence with respect to those claims
  is generally not relevant. That said, some evidence
  that touches on the unasserted claims could be
  relevant for some purpose. Accordingly the court finds
  that the motion in limine should be overruled at this
  time, without prejudice to its reassertion via timely
  objection to the admissibility of such evidence at
  trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BVROA003?jcsearch=2009%20BL%20222357&amp;summary=yes#jcite">Id. at *l-2</a>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BVROA003?jcsearch=2009%20BL%20222357&amp;summary=yes#jcite">2009 BL 222357</a>], 2009 U.S. Dist. LEXIS 96196, at
<i>*3-4.</i> Prior to trial, however, the district court
excluded R &amp; D's evidence on the <span CLASS="page_no" data-cite="2012 bl 5365 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[***6]</span> unasserted claims.
Specifically, the court orally ruled that, "[t]here is an issue
about the declaratory judgment and jurisdiction over the
unasserted claims of the patents. The validity of the
unasserted claims will not go to the jury. That's the way I
intend to proceed." J.A. 45134.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                     5. Jury Trial and JMOL Motions
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Beginning on October 19, 2009, the court conducted an eight-day
jury trial to address priority of invention, enablement,
damages, and willfulness. At the close of the evidence, both
parties moved for JMOL on the issues of enablement and
priority. The court noted that it had permitted the
presentation of enablement evidence to the jury so that the
court could get a clear understanding of the issue. Based on
the evidence adduced at trial, and before submitting the case
to the jury, the court granted JMOL for Streck on enablement,
explaining that "[e]verybody
<span CLASS="page_no" data-cite="665 f 3d 1279" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1279" data-primary-citation="665 F.3d 1269">[*1279]</span> 
agrees that if you use encapsulated reticulocytes that you
could use Dr. Ryan's invention to describe that." J.A. 46724.
The court further explained that "a pig reticulocyte is not a
human reticulocyte, so it's obviously an analog of a human
reticulocyte." <i><cite>Id</cite>.</i> Finally, the court stated that,
according to the evidence, it would make no difference whether
analog or true reticulocytes were used in Ryan's claimed
invention. With respect to priority, the court found that Ryan
was the first to conceive, but that there were substantial
factual disputes as to whether Johnson was the first to invent.
Accordingly, the only issues submitted to the jury were R
&amp; D's priority counterclaim, and Streck's damages and willful
infringement claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 28, 2009, the jury found that: (1) R &amp; D had not
proven, by clear and convincing evidence, that it was the first
to invent; and (2) R &amp; D had not willfully infringed
Streck's patents. The jury found that Streck was entitled to a
royalty for R &amp; D's infringing sales and awarded damages of
12.5%, which amounted to $92,298.88 plus costs and interest.
The court entered judgment in favor of Streck on October 29,
2009.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
         6. The Concurrent Interference Proceedings and Streck's
                              <cite>&sect; 146</cite> Action
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  While the infringement litigation was progressing, R &amp; D's
interference request was pending with the PTO, and, on March
21, 2007, the PTO declared an interference ("the PTO
Interference") between five of Streck's patents (the
patents-in-suit as well as U.S. Patent Nos. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3100633HOJ?jcsearch=usp%206403377&amp;summary=yes#jcite">6,403,377</a> and
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3100C90H8J?jcsearch=usp%206406915&amp;summary=yes#jcite">6,406,915</a>) and R &amp; D's pending patent application. The sole
count in the PTO Interference was Count 1, which corresponded
to Claim 1 of Streck's &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a>, and is identical to
the representative claim in this appeal.<a HREF="#fn900" name="fnref_fn900">[fn9]</a> On August 14,
2007, the district court denied R &amp; D's motion to stay the
infringement suit pending resolution of the PTO Interference,
and the two cases proceeded concurrently.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The PTO Board of Patent Appeals and Interferences ("the Board")
heard the parties' arguments regarding priority of invention in
February 2009. On November 2, 2009, just four days after the
district court entered judgment in this case, the Board issued
its priority decision. Unlike the jury in this case, which
found priority for Streck, the Board found that R &amp; D had
proven, by a preponderance <span CLASS="page_no" data-cite="2012 bl 5365 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[***7]</span> of the evidence, that Johnson was
the first to invent the claimed integrated control.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On November 13, 2009, Streck appealed the Board's interference
decision to the district <span CLASS="page_no" data-cite="101 uspq 2d 1231" data-cite-type="ReporterOfDecisions" data-cite-pageno="1231" data-primary-citation="101 U.S.P.Q.2d 1225">[**1231]</span> court under <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XEJ016003?jcsearch=35%20usc%20146&amp;summary=yes#jcite">35 U.S.C. &sect; 146</a>. The
<cite>&sect; 146</cite> appeal was assigned to the same judge who presided
over the infringement case. Because there was a complete
evidentiary record on the issue of priority &mdash; between the
trial and the proceedings before the Board &mdash; the parties
agreed to submit the <cite>&sect; 146</cite> action to the district court on
the admitted record without further discovery or offers of
proof.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
         7. Renewed Motion for JMOL, Motion for a New Trial, and
                            Injunctive Relief
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following the jury verdict and the Board's priority decision,
the parties filed three motions on November 12, 2009. First, R
&amp; D filed a renewed motion for JMOL and motion for a new
trial. In the motion, R &amp; D argued that the court should
enter judgment as a matter of law
<span CLASS="page_no" data-cite="665 f 3d 1280" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1280" data-primary-citation="665 F.3d 1269">[*1280]</span> 
on its counterclaim for invalidity because there was
"insufficient evidence as a matter of law to sustain the jury's
verdict that Defendants did not meet their burden of proving
that Dr. Johnson was the prior inventor by clear and convincing
evidence." J.A. 45059. Second, in light of the Board's decision
in the PTO Interference proceedings, R&amp; D moved to vacate
the judgment in this case, stay proceedings, and hold a new
trial. Finally, Streck filed a motion for permanent injunction
against R &amp; D to prevent future infringement of the
patents-in-suit. The parties agreed to defer judgment on
Streck's motion for injunctive relief and R &amp; D's motion
for a new trial until the district court ruled on the <cite>&sect; 146</cite>
action, so both could be appealed together to this court.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court issued three decisions on September 30,
2010. First, in the co-pending <cite>&sect; 146</cite> action, the court
reversed the Board's decision and found priority for Streck. As
discussed below, the <cite>&sect; 146</cite> action was at issue in a
companion appeal &mdash; Appeal No. 2011-1045 &mdash; which was
previously decided by this court. <i>See Streck, Inc. v.</i>
<i>Research &amp; Diagnostic Sys., Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GJH4I003?jcsearch=659%20f%203d%201186&amp;summary=yes#jcite">659 F.3d 1186</a>
(Fed. Cir. 2011). Second, in this case, the court denied R
&amp; D's renewed motion for JMOL and motion for a new trial. The
court found, in relevant part, that the evidence at trial
supported: (1) "the jury's finding that R &amp; D did not prove
by clear and convincing evidence that Dr. Johnson was the first
to invent an integrated reticulocyte control composition"; and
(2) "the court's finding as a matter of law that Streck's
patents were adequately enabled." <i>Denial of Renewed JMOL</i>
<i>Order</i>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 WL 3926059, at *9-10,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 U.S. Dist. LEXIS 104461,
at *32. Finally, the court granted Streck's motion for
a permanent injunction and assessed additional damages of
$36,690.18 for infringement occurring since the jury trial. The
court then enjoined R&amp; D from making, using or selling the
products at issue in this case "as well as any hematology
control products that are only colorably different therefrom in
the context of the infringed claims . . . and from otherwise
infringing the asserted claims of [the patents-in-suit] until
the expiration of the last to expire of the Patents-in-Suit."
J.A. 40047.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court denied R &amp; D's motion to stay the
injunction pending appeal to this court. Specifically, <span CLASS="page_no" data-cite="2012 bl 5365 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[***8]</span> the
court held that R &amp; D: (1) did not demonstrate a
likelihood of success on the merits regarding enablement,
priority, or lack of written description; (2) did not show it
would be irreparably harmed absent a stay because hematology
controls are only a small part of their business; and (3) did
not show that an injunction would hurt the public interest
because there was no showing that Streck would be unable to
meet the industry's demands for controls. R &amp; D was,
however, granted a sixty-day grace period to clear its
inventory because hematology controls are perishable products.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D timely appealed the September 30, 2010 district court
decisions to this court. This opinion relates solely to the
infringement action. We have jurisdiction pursuant to
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XEIMUG003?jcsearch=28%20U.S.C.%20%201295(a)(1)&amp;summary=yes#jcite">28 U.S.C. &sect; 1295</a>(a)(1).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               DISCUSSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, R&amp; D does not challenge the district court's
decision that its accused products literally infringe the
patents-in-suit as a matter of law. Instead. R &amp; D argues
that the district court erred when it: (1) dismissed R
&amp; D's invalidity counterclaims relating to the unasserted claims;
(2) granted summary judgment to Streck and denied R &amp; D's
cross-motion on written description; (3) granted JMOL for
Streck and denied R &amp; D's cross-motion on enablement; (4)
denied R &amp; D's motion
<span CLASS="page_no" data-cite="665 f 3d 1281" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1281" data-primary-citation="665 F.3d 1269">[*1281]</span> 
for renewed JMOL and motion for a new trial on priority;
and (5) issued an over-broad permanent injunction.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the reasons set forth below, we find that: (1) the district
court did not err in limiting the action to the claims Streck
asserted, given R &amp; D's failure to establish a case or
controversy with respect to the other claims; (2) the
patents-in-suit satisfy the written description requirement as
a matter of law, because the specification clearly discusses
true reticulocytes as well as analogs; (3) R &amp; D's evidence
failed to create a jury question on the <span CLASS="page_no" data-cite="101 uspq 2d 1232" data-cite-type="ReporterOfDecisions" data-cite-pageno="1232" data-primary-citation="101 U.S.P.Q.2d 1225">[**1232]</span> issue of whether the
patents-in-suit failed to enable one skilled in the art to make
the claimed integrated controls using true reticulocytes; (4)
the priority issue is controlled by this court's ruling in
<cite>Appeal No. 2011-1045</cite>, and R &amp; D's related evidentiary
challenges are without merit; and (5) properly construed, the
language in the permanent injunction is not overbroad.
Accordingly, we affirm the district court in full.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
               A. Jurisdiction Over the Unasserted Claims
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D sought summary judgment of invalidity with respect to
all claims of the patents-in-suit. In its summary judgment
order, the district court noted that: (1) Streck did not assert
infringement with respect to Claim 3 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500</a> and
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patents</a>; (2) R &amp; D "has no `reasonable
apprehension' it will face an infringement suit on any claims
other than those that Streck asserts it has infringed in this
action"; and (3) there is "nothing in the record to suggest any
intent to sue on the nonasserted claims." <i>Summary Judgment</i>
<i>Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 1000</a>. Although the district court
initially denied Streck's motion <i>in limine</i> to exclude
argument and evidence regarding the unasserted claims, just
before trial, the court stated that: "[t]here is an issue about
the declaratory judgment and jurisdiction over the unasserted
claims of the patents. The validity of the unasserted claims
will not go to the jury." <span CLASS="page_no" data-cite="2012 bl 5365 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[***9]</span> J.A. 45134.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D argues that the district court erroneously dismissed
its written description and enablement challenges with respect
to the unasserted claims. In support of this argument, R&amp; D
submits that the court applied an outdated "reasonable
apprehension of suit test" and that Streck's withdrawal of
claims "more than two years into this case" does not deprive
the court of jurisdiction over its invalidity
counter-claims.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> Appellant's Br. 34. R&amp; D also argues
that its counterclaim was sufficient to put Streck on notice
that all claims were at issue.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response, Streck argues that the district court correctly
dismissed R &amp; D's challenges to its unasserted claims.
Specifically, Streck contends that R &amp; D's counterclaim
only sought a declaration of invalidity with respect to the
"asserted claims" and, therefore, the court had jurisdiction
only over claims asserted at the time the relevant motions were
filed. For the reasons that follow, we conclude that the
district court did not err in finding that it lacked
jurisdiction over the unasserted claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is well-established that, in patent cases, the existence of
a "case or controversy must be evaluated on a claim-by-claim
basis." <i>Jervis B. Webb Co. v. So. Sys., Inc.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XN89HFQNB5G0?jcsearch=742%20f%202d%201388&amp;summary=yes#jcite">742 F.2d 1388</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XN89HFQNB5G0?jcsearch=742%20f%202d%201388&amp;summary=yes#jcite">1399</a> (Fed. Cir. 1984) (citations omitted). A party
claiming declaratory judgment jurisdiction has the burden of
showing "that the facts alleged,
<span CLASS="page_no" data-cite="665 f 3d 1282" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1282" data-primary-citation="665 F.3d 1269">[*1282]</span> 
`under all the circumstances, show that there is a
substantial controversy, between the parties having adverse
legal interests, of sufficient immediacy and reality to warrant
the issuance of a declaratory judgment.'" <i>Benitec Austl.,</i>
<i>Ltd. v. Nucleonics, Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17ATMK003?jcsearch=495%20f%203d%201340&amp;summary=yes#jcite">495 F.3d 1340</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17ATMK003?jcsearch=495%20f%203d%201340&amp;summary=yes#jcite">1343</a>
(Fed. Cir. 2007) (quoting <i>MedImmune, Inc. v. Genentech,</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. 118</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">127</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=166%20l%20ed%202d%20604&amp;summary=yes#jcite">166 L.Ed.2d 604</a>
(2007)). The party seeking a declaratory judgment must
establish that jurisdiction "existed at the time the claim for
declaratory relief was filed and that it has continued since."
<i></i><cite>Id. at 1344</cite>. (citing <i>Steffel v. Thompson</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=415%20us%20452&amp;summary=yes#jcite">415 U.S. 452</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=415%20us%20452&amp;summary=yes#jcite">459</a> n. 10, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=94%20supreme%20court%201209&amp;summary=yes#jcite">94 S.Ct. 1209</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=39%20l%20ed%202d%20505&amp;summary=yes#jcite">39 L.Ed.2d 505</a> (1974)). In
other words, jurisdiction must exist "at all stages of review,
not merely at the time the complaint [was] filed." <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17ATMK003?jcsearch=495%20F.3d%201340&amp;summary=yes#jcite">Id.
at 1345</a> (quoting <i>Steffel</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=415%20us%20452&amp;summary=yes#jcite">415 U.S. at 459</a> n. 10,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X5C8P4?jcsearch=94%20supreme%20court%201209&amp;summary=yes#jcite">94 S.Ct. 1209</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prior to the Supreme Court's decision in <i>Medlmmune</i>,
this court applied a two-part test to determine whether there
was an actual controversy in a declaratory judgment action.
Under the prior test, a declaratory judgment plaintiff had to
show: (1) an explicit action by the patentee that creates the
"reasonable apprehension" of an infringement suit; and (2)
present activity by the declaratory judgment plaintiff that
could constitute infringement or steps taken with intent to
infringe. <i>Gen-Probe Inc. v. Vysis, Inc.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X6CV07?jcsearch=359%20f%203d%201376&amp;summary=yes#jcite">359 F.3d 1376</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X6CV07?jcsearch=359%20f%203d%201376&amp;summary=yes#jcite">1380</a> (Fed. Cir. 2004). In <i>Medlmmune</i>, the Supreme
Court rejected strict reliance on the "reasonable apprehension
of suit" prong of the test. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 132</a> n. 11,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>; <i>see also SanDisk Corp. v. STMicroelectronics,</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">480 F.3d 1372</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X16I1RI003?jcsearch=480%20f%203d%201372&amp;summary=yes#jcite">1380</a> (Fed. Cir. 2007) ("The Supreme
Court's opinion in <i>Medlmmune</i> represents a rejection of
our reasonable apprehension of suit test.") The Court held that
there is no bright-line rule for determining whether an action
satisfies the case or controversy requirement and, instead,
what is required is:
<span CLASS="page_no" data-cite="101 uspq 2d 1233" data-cite-type="ReporterOfDecisions" data-cite-pageno="1233" data-primary-citation="101 U.S.P.Q.2d 1225">[**1233]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  that the dispute be definite and concrete, touching
  the legal relations <span CLASS="page_no" data-cite="2012 bl 5365 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[***10]</span> of parties having adverse legal
  interests; and that it be real and substantial and
  admit of specific relief through a decree of a
  conclusive character, as distinguished from an opinion
  advising what the law would be upon a hypothetical
  state of facts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Medlmmune</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 127</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a> (citations
and quotations omitted). After <i>Medlmmune</i>, courts must
look at "all the circumstances" to determine whether a
declaratory judgment plaintiff has shown a case or controversy
between the parties. As this court has explained, moreover,
although the Supreme Court rejected the reasonable apprehension
of suit test as the <i>sole</i> test for jurisdiction, "it
did not completely do away with the relevance of a reasonable
apprehension of suit." <i>Prasco, LLC v. Medicis Pharm.</i>
<i>Corp.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">537 F.3d 1329</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19E76Q003?jcsearch=537%20f%203d%201329&amp;summary=yes#jcite">1336</a> (Fed. Cir. 2008) (citing
<i>Caraco Pharm. Labs., Ltd. v. Forest Labs., Ltd.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d 1278</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">1291</a> (Fed. Cir. 2008)). Instead, in the wake of
<i>Medlmmune</i>, "proving a reasonable apprehension of suit
is one of multiple ways that a declaratory judgment plaintiff
can satisfy the more general all-the-circumstances test" to
establish jurisdiction. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19E76Q003?jcsearch=537%20F.3d%201329&amp;summary=yes#jcite">Id</a>.</i> (citing <i>Caraco</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X18N7CE003?jcsearch=527%20f%203d%201278&amp;summary=yes#jcite">527 F.3d at 1291</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <i>Post-Medlmmune</i>, at least one district court has found
that it lacked declaratory judgment jurisdiction over patent
claims that were initially asserted in a broad complaint and
subsequently not included in the narrower scope of claims
alleged to be infringed. <i>See Hoffman-La Roche Inc. v. Mylan</i>
<i>Inc.</i>, No. <cite>2:09-0192</cite>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 WL 4796736, at *5,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784, at *17-18 (D.N.J. Dec. 9, 2009). In
<i>Hoffman</i>, the plaintiff alleged infringement of a
patent that encompassed
<span CLASS="page_no" data-cite="665 f 3d 1283" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1283" data-primary-citation="665 F.3d 1269">[*1283]</span> 
six claims. <i><cite>Id</cite>.</i> at *2-3,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784,
at *8. After filing the complaint, the plaintiff served its
infringement contentions pursuant to the local patent
rules and asserted infringement with respect to only one of the six
claims. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">Id</a>.</i> at *3, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784, at
*9. The district court found that, with respect to claims that
were no longer asserted, the counterclaimant seeking
declaratory judgment "must meet its burden under
<i>Med-Immune</i> and show that a live case or controversy
exists and continues to exist on a claim-by-claim basis and at
every stage of the litigation." <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">Id</a>.</i> at *5,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784, at *17. The court concluded that the
plaintiffs decision to change its position did not
automatically divest the court of jurisdiction, but the
counterclaimant must show that jurisdiction continues to exist
with respect to the now unasserted claims. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20U.S.%20118&amp;summary=yes#jcite">Id</a>.</i> at *5,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784, at *18. Because the
counterclaimant failed to make that showing, the court found
that it lacked jurisdiction over those discrete claims.
<i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">Id</a>.</i> at *5-6, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1C7V5Q003?jcsearch=2009%20BL%20264324&amp;summary=yes#jcite">2009 BL 264324</a>], 2009 U.S. Dist. LEXIS 114784, at *20.
Although <i>Hoffman</i> is not binding on this court, we find
its analysis persuasive and agree that, consistent with
<i>Medlmmune</i>, a counterclaimant must show a continuing
case or controversy with respect to withdrawn or otherwise
unasserted claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Citing <i>Scanner Technologies Corp. v. ICOS Vision Systems</i>
<i>Corp.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20f%203d%201365&amp;summary=yes#jcite">528 F.3d 1365</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20f%203d%201365&amp;summary=yes#jcite">1382-83</a> (Fed. Cir. 2008), R &amp; D
argues that "a patentee cannot dictate the scope of a duly
filed counterclaim simply by withdrawing some, but not all, of
the asserted patent claims from the lawsuit." Appellants' Br.
34. As Streck argues, however, R &amp; D's reliance on
<i>Scanner Technologies</i> is misplaced, particularly since
the circumstances here are readily distinguishable.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In <i>Scanner <span CLASS="page_no" data-cite="2012 bl 5365 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[***11]</span> Technologies</i>, the patent holder filed suit
alleging infringement, and the defendant counterclaimed seeking
a declaration that both of the patents-in-suit were invalid,
unenforceable, and not infringed. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20f%203d%201365&amp;summary=yes#jcite">528 F.3d at 1371</a>. The parties
stipulated that the case "would rise and fall" on one claim of
one of the patents, and, based on that stipulation, the
district court analyzed only that one claim in its infringement
analysis. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20F.3d%201365&amp;summary=yes#jcite">Id</a>.</i> The district court then found that the
claims of both patents-in-suit were invalid as obvious and
entered summary judgment of noninfringement. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20F.3d%201365&amp;summary=yes#jcite">Id.
at 1373</a>. The patentee appealed, arguing, among other things, that
the district court lacked jurisdiction to adjudicate and
invalidate claims other than the single claim at issue in the
infringement analysis. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20F.3d%201365&amp;summary=yes#jcite">Id. at 1383</a>. Although the
parties had stipulated that the case would be tried on a
representative claim, we found that the district court
nonetheless had jurisdiction over all of the claims because the
defendant asserted a counter-claim seeking declaratory judgment
on all claims of the patents-in-suit. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20F.3d%201365&amp;summary=yes#jcite">Id. at 1383-84</a>.
Specifically, we found that the "pleadings represented that
`the case' constituted allegations of infringement of both
patents, and a declaratory judgment action seeking invalidity,
noninfringement, and unenforceability of all the claims of the
patent in suit." <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X193VQC003?jcsearch=528%20F.3d%201365&amp;summary=yes#jcite">Id. at 1383-84</a>. As such, the district
court had jurisdiction to invalidate the claims of both
patents-in-suit.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Unlike the situation in <i>Scanner Technologies</i>, where
the parties stipulated that the court need only analyze one
"representative" claim to decide infringement, and the patentee
never affirmatively disclaimed its allegations of infringement
<span CLASS="page_no" data-cite="101 uspq 2d 1234" data-cite-type="ReporterOfDecisions" data-cite-pageno="1234" data-primary-citation="101 U.S.P.Q.2d 1225">[**1234]</span> as to the other claims, here, as in <i>Hoffman</i>, the
patentee narrowed the scope of its claims at the start of
litigation pursuant to the local patent rules and did so even
further before any dispositive rulings by the court.
<span CLASS="page_no" data-cite="665 f 3d 1284" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1284" data-primary-citation="665 F.3d 1269">[*1284]</span> 
Streck filed its Complaint in June 2006, alleging
infringement of "one or more claims" of each of the
patents-in-suit. In December 2006, Streck served its
preliminary infringement contentions, which narrowed the scope
of claims at issue to fifteen specific claims.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> In
response, R &amp; D's counterclaim was limited to the "asserted
claims," and its initial invalidity contentions, which were
served on January 19, 2007, addressed the same fifteen claims
identified in Streck's infringement contentions. The number of
asserted claims was narrowed again, moreover, by no later than
May 2009, this time to only nine claims. Therefore, unlike the
situation in <i>Scanner Technologies</i>, where all of the
claims were at issue and were never with-drawn or altered by
either party, here, both parties were on notice from the start
of litigation that the scope of claims at issue was only a
subset of the full patents-in-suit and, significantly, did not
include Claim 3 of any patent. And, the parties knew precisely
which claims were at issue well before the court ruled on the
parties' summary judgment motions or conducted trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R&amp; D relies primarily on its assertion that, under
<i>MedImmune</i>, it need not prove reasonable <span CLASS="page_no" data-cite="2012 bl 5365 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[***12]</span> apprehension
of an infringement suit to vest jurisdiction over its
invalidity counterclaims in the district court. Though R
&amp; D is correct that the reasonable apprehension of suit test is
no longer the exclusive test for declaratory judgment
jurisdiction, <i>Medlmmune</i> does not stand for the
proposition that an Article III case or controversy exists
automatically when-ever a competitor desires to mount a
validity challenge. Under <i>MedImmune</i>, a party seeking
declaratory judgment still "has the burden of establishing the
existence of an actual case or controversy." <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=549%20us%20118&amp;summary=yes#jcite">549 U.S. at 140</a>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XRI92FQNB5G0?jcsearch=127%20supreme%20court%20764&amp;summary=yes#jcite">127 S.Ct. 764</a>. Thus, although the district court relied on
pre-<i>Medlmmune</i> case law in its summary judgment order,
and incorrectly relied on the absence of a "reasonable
apprehension" of suit to defeat jurisdiction, considering the
totality of the circumstances, we agree with the district
court's determination that it lacked jurisdiction over the
unasserted claims. Importantly, there is no evidence that
R&amp; D met its burden of showing a continuing case or
controversy with respect to the unasserted claims. Indeed,
R&amp; D does not seriously argue here that it did so, relying
instead only on the district court's misstatement of current
governing law.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a> Because, applying <i>MedImmune</i>, we
find that the district court did not have jurisdiction over the
unasserted claims, we affirm its decision not to address them.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                         B. Written Description
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court found that Streck's patents-in-suit
satisfied the written description requirement as a matter of
law. <i>Summary Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 999</a>. In
support of this conclusion, the court found that: (1) Claim 4
of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 patent</a> discloses a composition "wherein the
reticulocyte component comprises reticulocytes prepared by
isolation from whole blood"; and (2) the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668</a> and
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patents</a> "contain additional disclosure of the use of
reticulocytes isolated from the blood of anemic animals."
<i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20F.%20Supp.%202d%20988&amp;summary=yes#jcite">Id</a>.</i>
<span CLASS="page_no" data-cite="665 f 3d 1285" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1285" data-primary-citation="665 F.3d 1269">[*1285]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D argues that the district court erred because "[t]he
patents-in-suit failed to provide sufficient details for [a]
person of ordinary skill in the art to understand that Ryan was
in possession of a true reticulocyte integrated control."
Appellants' Br. 35. R &amp; D asks this court to grant its
motion for summary judgment that Streck's patents are invalid
for lack of written description or, in the alternative, remand
the written description issue for a jury trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Streck responds by pointing to specific disclosures in the
patents-in-suit as evidence that the asserted claims are
adequately described. In light of these disclosures, which are
discussed below, Streck argues that the district court
correctly found that the claims and specifications of the
patents-in-suit are sufficient to satisfy the written
description requirement as a matter of law. We agree.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Written description is a statutory requirement set forth in
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XEIVVO003?jcsearch=35%20U.S.C.%20%20112&amp;summary=yes#jcite">Section 112</a> provides, in relevant part, that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The specification <i>shall contain a written</i>
  <i>description of the invention</i>, and of the manner
  and process of making and using it, in such full,
  clear, concise, and exact terms as to enable any
  person skilled in the art to <span CLASS="page_no" data-cite="101 uspq 2d 1235" data-cite-type="ReporterOfDecisions" data-cite-pageno="1235" data-primary-citation="101 U.S.P.Q.2d 1225">[**1235]</span> which it pertains, or
  with which it <span CLASS="page_no" data-cite="2012 bl 5365 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[***13]</span> is most nearly connected, to make and
  use the same . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XEIVVO003?jcsearch=35%20usc%20112&amp;summary=yes#jcite">35 U.S.C. &sect; 112</a>, para. 1 (emphasis added). The written
description "must clearly allow persons of ordinary skill in
the art to recognize that [the inventor] invented what is
claimed." <i>Ariad Pharm., Inc. v. Eli Lilly &amp; Co.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d 1336</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">1351</a> (Fed. Cir. 2010) (en banc) (citation and
quotations omitted). The test is whether the disclosure
"conveys to those skilled in the art that the inventor had
possession of the claimed subject matter as of the filing
date." <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id</a>.</i> This test requires an "objective inquiry
into the four corners of the specification from the perspective
of a person of ordinary skill in the art." <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id</a>.</i> Given
this perspective, in some instances, a patentee can rely on
information that is "well-known in the art" to satisfy written
description. <i>Boston Sci. Corp. v. Johnson</i>
<i>&amp; Johnson</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1FHTAM003?jcsearch=647%20f%203d%201353&amp;summary=yes#jcite">647 F.3d 1353</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1FHTAM003?jcsearch=647%20f%203d%201353&amp;summary=yes#jcite">1366</a> (Fed. Cir. 2011). Where,
however, the "four corners of the specification directly
contradict information that the patentee alleges is Veil-known'
to a person of skill at the effective filing date, no
reasonable jury could conclude that the patentee possessed the
invention." <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1FHTAM003?jcsearch=647%20F.3d%201353&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  It is well-established that the "hallmark of written
description is disclosure." <i>Ariad</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d at 1351</a>.
The level of detail required to satisfy the written description
requirement depends, in large part, on the nature of the claims
and the complexity of the technology. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id</a>.</i> As we
explained in <i>Ariad</i>, the written description
requirement "does not demand either examples or an actual
reduction to practice; a constructive reduction to practice
that in a definite way identifies the claimed invention can
satisfy the written description requirement." <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">Id.
at 1352</a> (citing <i>FalkoGunter Falkner v. Inglis</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X153MP6003?jcsearch=448%20f%203d%201357&amp;summary=yes#jcite">448 F.3d 1357</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X153MP6003?jcsearch=448%20f%203d%201357&amp;summary=yes#jcite">1366-67</a> (Fed. Cir. 2006)). That said, a "mere wish or plan"
to obtain the claimed invention is not sufficient. <i>Centocor</i>
<i>Ortho Biotech, Inc. v. Abbott Labs.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1F0OCC003?jcsearch=636%20f%203d%201341&amp;summary=yes#jcite">636 F.3d 1341</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1F0OCC003?jcsearch=636%20f%203d%201341&amp;summary=yes#jcite">1348</a>
(Fed. Cir. 2011) (citing <i>Regents of the Univ. of Cal. v. Eli</i>
<i>Lilly &amp; Co.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XAC9DA?jcsearch=119%20f%203d%201559&amp;summary=yes#jcite">119 F.3d 1559</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XAC9DA?jcsearch=119%20f%203d%201559&amp;summary=yes#jcite">1566</a> (Fed. Cir. 1997)).
"Compliance with the written description requirement is a
question of fact but is amenable to summary judgment in cases
where no reasonable fact finder could return a verdict for the
nonmoving party." <i>PowerOasis, Inc. v. T-Mobile USA</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X18OV00003?jcsearch=522%20f%203d%201299&amp;summary=yes#jcite">522 F.3d 1299</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X18OV00003?jcsearch=522%20f%203d%201299&amp;summary=yes#jcite">1307</a> (Fed. Cir. 2008).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_386177">[2]</span> The pivotal issue here is whether the patents-in-suit provide
adequate written
<span CLASS="page_no" data-cite="665 f 3d 1286" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1286" data-primary-citation="665 F.3d 1269">[*1286]</span> 
description for integrated controls using either true
reticulocytes or reticulocyte analogs. According to R &amp; D,
the patents-in-suit fail to demonstrate that Ryan possessed and
invented an integrated control using true reticulocytes. In
support of this argument, R &amp; D asserts that: (1) "Ryan was
unable to locate any description of the use of true
reticulocytes in his own patents" when asked to do so during
his deposition; (2) Ryan did not consider true reticulocytes to
be part of his invention; and (3) "Streck had never attempted
to make a true reticulocyte integrated control." Appellants'
Br. 36.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D mischaracterizes Ryan's testimony, however. Although
Ryan initially testified that he did not know if he could point
to anything specific in the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a> describing the
use of true reticulocytes rather than analogs in an integrated
control, he subsequently reviewed the patent and pointed to
language providing that "the reticulocyte <span CLASS="page_no" data-cite="2012 bl 5365 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[***14]</span> component may
comprise true mammalian reticulocytes prepared for instance by
mammalian red blood cell encapsulation or by isolation from
whole blood." J.A. 43601:2-13. Based on this language, Ryan
clarified that the Patent specifically "covers both kinds" of
reticulocytes. <i><cite>Id</cite>.</i> And, the mere fact that Ryan chose
to reduce his invention to practice using a reticulocyte analog
rather than a true reticulocyte is not relevant to the written
description inquiry. Although R &amp; D contends that Streck
"did not posses true reticulocyte integrated controls," Streck
is not required to prove an actual reduction to practice as to
all disclosures. <i>See Ariad</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20f%203d%201336&amp;summary=yes#jcite">598 F.3d at 1352</a>. Instead,
to satisfy written description, Streck need only show that the
specification itself demonstrates "a constructive reduction to
practice that in a definite way identifies the claimed
invention." <i>See </i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CS7VQ003?jcsearch=598%20F.3d%201336&amp;summary=yes#jcite">id. at 1352</a>. The relevant inquiry,
therefore, is whether a person of ordinary skill in the
art would reasonably find that the patent sufficiently described
the invention using true reticulocytes. R &amp; D's expert, Dr.
Simson, testified that, in this case, a person of ordinary
skill in the art is "someone with an advanced degree like an
M.D. or a Ph.D. and with experience in the field." J.A.
46608:10-12.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Looking to the specifications, the patents-in-suit refer to
several types of true reticulocytes:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  [T]he control may suitably contain stabilized
  reticulocytes (that is, immature anucleate red blood
  cells containing some <span CLASS="page_no" data-cite="101 uspq 2d 1236" data-cite-type="ReporterOfDecisions" data-cite-pageno="1236" data-primary-citation="101 U.S.P.Q.2d 1225">[**1236]</span> ribonucleic acid) or an analog
  thereof. For example, among possible embodiments,
  <i>the reticulocyte component may comprise true</i>
  <i>mammalian reticulocytes prepared for instance by</i>
  <i>mammalian (e.g. human) red blood cell encapsulation or</i>
  <i>by isolation from whole blood.</i> The reticulocyte
  component is prepared in any suitable manner. See,
  e.g. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">U.S. Pat. No. 5,432,089</a>, incorporated by
  reference. <i>Alternatively, it is possible to obtain</i>
  <i>suitable reticulocytes by obtaining blood from an</i>
  <i>anemic animal (e.g., a pig, goat, rabbit or the</i>
  <i>like</i>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> col.3 11.17-25 (emphases added). Likewise,
the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a> provides that: "Among possible
embodiments, the reticulocyte component may comprise true
mammalian reticulocytes prepared for instance by mammalian
(e.g. human) red blood cell encapsulation or by isolation from
whole blood." &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a> col.2 11.37-42. These
disclosures demonstrate that Ryan invented the claimed
integrated control using <i>both</i> true reticulocytes and
reticulocyte analogs. Further, as Streck points out in its
brief, this is not a case where a patentee attempts to claim a
broad genus without defining specific species. Instead, as
noted, Streck listed several
<span CLASS="page_no" data-cite="665 f 3d 1287" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1287" data-primary-citation="665 F.3d 1269">[*1287]</span> 
specific true reticulocytes in its specifications.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  According to R &amp; D, Ryan testified that true reticulocytes
were not part of his invention. Contrary to R &amp; D's
suggestion, however, Ryan never said that the claimed
integrated controls could not be made using true reticulocytes.
To the extent Ryan testified about the difficulty of using true
reticulocytes in controls, the district court found that his
testimony "relate[d] to the commercial practicalities of use of
true reticulocytes on a large <span CLASS="page_no" data-cite="2012 bl 5365 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[***15]</span> scale and not to the feasibility
or viability of true reticulocytes in a control." <i>Summary</i>
<i>Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 999</a>. We agree with the
district court that Ryan's testimony, when taken in context,
merely reflected his personal preference for using analogs in
integrated controls.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The district court properly concluded that one skilled in the
art would have recognized that the claimed integrated controls
could be made using either true reticulocytes or reticulocyte
analogs. This is particularly true given the evidence that
analogs are designed to mimic true reticulocytes and that use
of true reticulocytes in stand-alone controls was well-known in
the prior art. Given the language in the patents-in-suit,
coupled with the well-known use of true reticulocytes in the
prior art, a person of ordinary skill would understand the
patent to include integrated controls using true reticulocytes.
Accordingly, we affirm the district court's decision granting
Streck's motion for summary judgment on written description.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              C. Enablement
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At the close of the evidence, but before the case went to the
jury, the district court granted JMOL that the patents-in-suit
enabled the claimed integrated hematology control using both
true reticulocytes and reticulocyte analogs. When reviewing a
district court's grant or denial of a motion for JMOL, this
court applies the procedural law of the relevant regional
circuit, here the Eighth Circuit. <i>Trading Techs. Int'l Inc.</i>
<i>v. eSpeed, Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CJOFK003?jcsearch=595%20f%203d%201340&amp;summary=yes#jcite">595 F.3d 1340</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CJOFK003?jcsearch=595%20f%203d%201340&amp;summary=yes#jcite">1357</a> (Fed. Cir. 2010). The
Eighth Circuit reviews a district court's grant or denial of
JMOL <i>de novo</i>, applying the same standard as the
district court. <i>Synergetics, Inc. v. Hurst</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X168D38003?jcsearch=477%20f%203d%20949&amp;summary=yes#jcite">477 F.3d 949</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X168D38003?jcsearch=477%20f%203d%20949&amp;summary=yes#jcite">956</a> (8th Cir. 2007) (citation omitted). To grant judgment
as a matter of law, the court must find that there is "no
legally sufficient basis to support a jury verdict in the
non-moving party's favor." <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X168D38003?jcsearch=477%20F.3d%20949&amp;summary=yes#jcite">Id</a>.</i> (citing Fed.R.Civ.P.
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X144L3U003?jcsearch=frcp%2050&amp;summary=yes#jcite">50</a>(a)(1)). All factual inferences are drawn in favor of the
non-moving party. <i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X168D38003?jcsearch=477%20F.3d%20949&amp;summary=yes#jcite">Id</a>.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although R&amp; D concedes that the patents-in-suit enable the
use of reticulocyte analogs in an integrated control, it argues
that they do not enable true reticulocyte integrated controls.
First, R&amp; D argues that the district court erred by failing
to assess whether the patents-in-suit enable the novel aspect
of the claimed invention: making and using true reticulocytes
in an integrated control. According to R &amp; D, the court
improperly relied on prior art and knowledge of those skilled
in the art to "fill in the missing disclosure as to the novel
aspect of integrating true reticulocytes into whole blood
controls." Appellants' Br. 43. In support of this argument,
R&amp; D points to the testimony of one of Streck's experts,
James Janik, who testified that the patents-in-suit mention use
of true reticulocytes in an integrated control but do not
"discuss it in any other detail." J.A. 45879:18-22. Second,
R&amp; D submits that the court erred in granting JMOL in favor
of Streck because the patents-in-suit do not enable a true
reticulocyte integrated control without "undue
experimentation." R&amp; D asks this court to grant its motion
for JMOL, or, in the alternative,
<span CLASS="page_no" data-cite="665 f 3d 1288" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1288" data-primary-citation="665 F.3d 1269">[*1288]</span> 
remand the enablement <span CLASS="page_no" data-cite="2012 bl 5365 p 16" data-cite-type="Bloomberg" data-cite-pageno="16" data-primary-citation="">[***16]</span> issue for a jury trial.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In response, Streck claims that: (1) the "novel aspect" of the
patents-in-suit is "an <i>integrated<span CLASS="page_no" data-cite="101 uspq 2d 1237" data-cite-type="ReporterOfDecisions" data-cite-pageno="1237" data-primary-citation="101 U.S.P.Q.2d 1225">[**1237]</span> </i> reticulocyte
control, i.e., a single control containing both a reticulocyte
component and a white blood cell component capable of
exhibiting a five-part differential"; (2) the patents-in-suit
enable the use of true reticulocytes in such integrated
controls because true reticulocytes are "virtually
indistinguishable" from analogs; (3) R &amp; D failed in its
burden to prove invalidity by clear and convincing evidence;
and (4) R &amp; D's expert testimony was conclusory and legally
insufficient to preclude JMOL. Appellee's Br. 35, 37. For the
reasons articulated below, we find Streck's arguments
well-taken.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Enablement "is a legal determination of whether a patent
enables one skilled in the art to make and use the claimed
invention." <i>Hybritech Inc. v. Monoclonal Antibodies,</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XAFG3G?jcsearch=802%20f%202d%201367&amp;summary=yes#jcite">802 F.2d 1367</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XAFG3G?jcsearch=802%20f%202d%201367&amp;summary=yes#jcite">1384</a> (Fed. Cir. 1986) (citation
omitted). To be enabling, a patent's specification must "teach
those skilled in the art how to make and use the full scope of
the claimed invention without `undue experimentation.'"
<i>ALZA Corp. v. Andrx Pharm., LLC</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1D33TU003?jcsearch=603%20f%203d%20935&amp;summary=yes#jcite">603 F.3d 935</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1D33TU003?jcsearch=603%20f%203d%20935&amp;summary=yes#jcite">940</a>
(Fed. Cir. 2010) (citations omitted). It is well-established,
however, that a specification need not disclose what is
well-known in the art. <i>See Hybritech</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/XAFG3G?jcsearch=802%20f%202d%201367&amp;summary=yes#jcite">802 F.2d at 1384</a>
("[A] patent need not teach, and preferably omits, what is well
known in the art."). It is true, however, that, "the rule that
a specification need not disclose what is well known in the
art is merely a rule of supplementation, not a substitute for a
basic enabling disclosure." <i>ALZA</i> <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1D33TU003?jcsearch=603%20f%203d%20935&amp;summary=yes#jcite">603 F.3d at 940-41</a>
(quoting <i>Auto. Techs. Int'l Inc. v. BMW of N. Am.,</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20f%203d%201274&amp;summary=yes#jcite">501 F.3d 1274</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20f%203d%201274&amp;summary=yes#jcite">1282</a> (Fed. Cir. 2007)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The enablement requirement is met where one skilled in the
art, having read the specification, could practice the invention
without "undue experimentation." <i>In re Wands, </i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3I6GB?jcsearch=858%20F.2d%20731&amp;summary=yes#jcite">858 F.2d
731</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3I6GB?jcsearch=736-37&amp;summary=yes#jcite">736-37</a> (Fed. Cir. 1988) ("Enablement is not precluded by the
necessity for some experimentation such as routine
screening."). Whether undue experimentation is required "is not
a single, simple factual determination, but rather is a
conclusion reached by weighing many factual considerations."
<i>ALZA</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1D33TU003?jcsearch=603%20f%203d%20935&amp;summary=yes#jcite">603 F.3d at 940</a> (citing <i>Wands</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3I6GB?jcsearch=858%20f%202d%20731&amp;summary=yes#jcite">858 F.2d at 737</a>). In <i>Wands</i>, this court set forth the following
factors to consider when determining whether a disclosure
requires undue experimentation:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  (1) the quantity of experimentation necessary, (2) the
  amount of direction or guidance presented, (3) the
  presence or absence of working examples, (4) the
  nature of the invention, (5) the state of the prior
  art, (6) the relative skill of those in the art, (7)
  the predictability or unpredictability of the art, and
  (8) the breadth of the claims.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X3I6GB?jcsearch=858%20f%202d%20731&amp;summary=yes#jcite">858 F.2d at 737</a>. "[I]t is not necessary that a court review all
the <i>Wands</i> factors to find a disclosure enabling. They
are illustrative, not mandatory." <i>Amgen, Inc. v. Chugai</i>
<i>Pharm. Co.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X31TSG?jcsearch=927%20f%202d%201200&amp;summary=yes#jcite">927 F.2d 1200</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X31TSG?jcsearch=927%20f%202d%201200&amp;summary=yes#jcite">1213</a> (Fed. Cir. 1991).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "Enablement is a matter of law that we review without
deference; however, this Court reviews the factual
underpinnings of enablement for substantial evidence."
<i>Martek Biosciences Corp. v. Nutrinova, Inc.</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BLN4S003?jcsearch=579%20f%203d%201363&amp;summary=yes#jcite">579 F.3d 1363</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1BLN4S003?jcsearch=579%20f%203d%201363&amp;summary=yes#jcite">1378</a> (Fed. Cir. 2009) (quotations and citation omitted).
Because patents are presumed valid, lack of enablement must be
shown by clear and convincing evidence. <i>ALZA</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1D33TU003?jcsearch=603%20f%203d%20935&amp;summary=yes#jcite">603 F.3d at 940</a> (citing <i>Auto. Techs.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20f%203d%201274&amp;summary=yes#jcite">501 F.3d at 1281</a>).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D relies on <i>Automotive <span CLASS="page_no" data-cite="2012 bl 5365 p 17" data-cite-type="Bloomberg" data-cite-pageno="17" data-primary-citation="">[***17]</span> Technologies</i> for the
proposition that, "when the patentee broadly claims two
distinct species,
<span CLASS="page_no" data-cite="665 f 3d 1289" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1289" data-primary-citation="665 F.3d 1269">[*1289]</span> 
it must enable both." Appellants' Br. 43. <i>Automotive</i>
<i>Technologies</i> involved a side-impact crash sensor for an
automobile airbag, and the district court construed the claims
to include both mechanical and electronic side-impact sensors.
One of the defendants moved for summary judgment that the
claims covering an electronic sensor were invalid for lack of
enablement. <i>Auto. Techs.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20f%203d%201274&amp;summary=yes#jcite">501 F.3d at 1279-80</a>. The
district court granted the motion on grounds that the
specification failed to provide adequate detail to teach a
person of skill in the art to make an electronic sensor without
undue experimentation. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20F.3d%201274&amp;summary=yes#jcite">Id. at 1280</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On appeal, this court found that the electronic sensors were
novel for side-impact crash sensing and agreed with the
district court that the patentee had not disclosed sufficient
detail to make a side-impact electronic sensor. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20F.3d%201274&amp;summary=yes#jcite">Id.,
at 1283-84</a>. In reaching this conclusion, we reviewed the
specification and noted that, although it detailed mechanical
side-impact sensors, there was only one short paragraph and one
figure showing an electronic sensor. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20F.3d%201274&amp;summary=yes#jcite">Id. at 1282</a>. We
explained that "[e]lectronic side impact sensors are not just
another known species of a genus consisting of sensors, but are
a distinctly different sensor compared with the well-enabled
mechanical side impact sensor that is fully discussed in the
specification." <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20F.3d%201274&amp;summary=yes#jcite">Id. at 1285</a>. We disagreed with the
patentee's argument that the knowledge of one skilled in the
art could supply the <span CLASS="page_no" data-cite="101 uspq 2d 1238" data-cite-type="ReporterOfDecisions" data-cite-pageno="1238" data-primary-citation="101 U.S.P.Q.2d 1225">[**1238]</span> missing information regarding how the
electronic sensor operates, and reiterated that the
specification, not the knowledge of those skilled in the
art, "must supply the novel aspects of an invention" to satisfy the
enablement requirement. <i></i><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X17JRGU003?jcsearch=501%20F.3d%201274&amp;summary=yes#jcite">Id. at 1283</a> (citing
<i>Genentech, Inc. v. Novo Nordisk A/S</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">108 F.3d 1361</a>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X4K9GE?jcsearch=108%20f%203d%201361&amp;summary=yes#jcite">1366</a> (Fed. Cir. 1997)).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although R &amp; D argues that "Streck presented no evidence
that the preparation and stabilization methods used for true
reticulocyte stand-alone controls would work with integrated
reticulocyte controls," the burden was on R &amp; D to show
invalidity by clear and convincing evidence. <i>See</i>
Appellants' Br. 47. The question here is whether there was a
legitimate issue of fact regarding enablement &mdash; i.e.,
regarding whether the specification contains sufficient
information to enable a person skilled in the art to make
integrated hematology controls using either true reticulocytes
or reticulocyte analogs. After full review of the record, we
agree with the district court that, considering its burden at
trial, R&amp;D failed to submit sufficient evidence from which
a jury could reasonably conclude that one skilled in the
art could not have followed Streck's specification to substitute
true reticulocytes for Ryan's reticulocyte analog in the
claimed control.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_386178">[3]</span> Unlike the situation in <i>Automotive Technologies</i>, where
the electronic sensors differed in structure and operation from
mechanical sensors, here, there was unrebutted evidence that
true reticulocytes and Ryan's reticulocyte analogs "work in
exactly the same way in a hematology control, and are <span CLASS="page_no" data-cite="2012 bl 5365 p 18" data-cite-type="Bloomberg" data-cite-pageno="18" data-primary-citation="">[***18]</span> virtually
indistinguishable, even to one skilled in the art." Appellee's
Br. 39. Indeed, the patents-in-suit incorporate by reference
Ryan's prior patent for a stand-alone control using
reticulocyte analogs: U.S. Patent No. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">5,432,089</a> ("the
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089 Patent</a>"). <i>See</i> &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> col.3
11.16-23. The &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089 Patent</a> describes how reticulocyte
analogs are made and explains that the "synthetic reticulocytes
which are used in the reference control of the invention
exhibit a reticulocyte continuum and distribution that is
similar to that of normal human reticulocytes." &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089
Patent</a> col.8 11.35-43. As such, the specification, and the
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X2H0C40428J?jcsearch=usp%205432089&amp;summary=yes#jcite">089 Patent</a> incorporated by reference therein, support
Streck's position
<span CLASS="page_no" data-cite="665 f 3d 1290" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1290" data-primary-citation="665 F.3d 1269">[*1290]</span> 
that true reticulocytes and reticulocyte analogs work in the
same way in a hematology control.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  At trial, moreover, Ryan testified that "I would dare say
hardly anyone I know could tell the difference between [analog]
and standard reticulocytes." J.A. 45587:6-7. Similarly, another
Streck expert, Mr. Scholl, testified that "under a microscope
[analogs] are very similar to human reticulocytes." J.A.
45518:21-24. In other words, the enabling disclosure in
Streck's patents for use of reticulocyte analogs is equally
enabling with respect to true reticulocytes, and, importantly,
R &amp; D failed to offer evidence to the contrary.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R&amp; D also failed to produce adequate evidence that the
experimentation required to create a true reticulocyte
integrated control would be unduly laborious for one of
ordinary skill in the art. R&amp; D relies primarily on its own
expert, Dr. Simson, who testified that "the patents do not
enable a person of ordinary skill in the art to make . . . an
integrated control preparation containing naturally occurring
reticulocytes." J.A. 46613:9-12. Simson further testified that
"there is no real description in the patent itself enabling one
to do it" and there were no examples "of how to make this
material using natural occurring reticulocytes" in the patents.
J.A. 46610:25-46611:5. As Streck argues, however, conclusory
expert assertions do not give rise to a genuine issue of
material fact. Although Simson testified that "a large amount
of experimentation" would be necessary, on cross-examination he
admitted, after he was presented with his own conflicting
deposition testimony, that he has never been involved in
developing controls. <i>See</i> J.A. 46611:19-24;
46621:13-46622:20.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although R &amp; D argues that Ryan and Scholl admitted that
the quantity of experimentation to make and use a true
reticulocyte integrated control would be high, R &amp; D
mischaracterizes this testimony. Indeed, when taken in context,
most of the testimony R&amp; D cites was referring to the
difficulty that would have been experienced in attempting to
combine a reticulocyte into an integrated control
<i>prior</i> to Ryan's disclosure. For example, when asked
about developing a control, Ryan responded that: "sometimes
it's pretty hard . . . I think that usually when we have to
make a control, three or four of us will work on it and it may
take us anyway [sic] from one to two years. So it doesn't
happen instantaneously." J.A. 45596:5-9. Ryan clarified that
statement, however, when he noted that development and <span CLASS="page_no" data-cite="2012 bl 5365 p 19" data-cite-type="Bloomberg" data-cite-pageno="19" data-primary-citation="">[***19]</span> testing
for a true reticulocyte integrated control would be "a lot less
for the obvious reason that I have already gone through the
process once. Going through with a different analog, with an
animal analog, shouldn't be that much harder." J.A.
45714:14-17. Ryan further <span CLASS="page_no" data-cite="101 uspq 2d 1239" data-cite-type="ReporterOfDecisions" data-cite-pageno="1239" data-primary-citation="101 U.S.P.Q.2d 1225">[**1239]</span> testified that a person skilled in
the art knew that true reticulocytes could be used in controls
and that he had, in fact, previously developed stand-alone
controls using animal cells.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  During cross-examination, when asked whether anyone at Streck
ever tried to make an integrated control using a true
reticulocyte, Scholl testified that, although he was not aware
of any instances, "we knew that we could if we wanted to." J.A.
45539:12. Scholl then testified that "some testing" would be
required to use a true reticulocyte in an integrated control
but that "the same technology would be involved with either one
of the two types of reticulocytes." <i>See</i> J.A.
45539:16-45540:17. Likewise, when asked whether it would be
difficult to use a true human reticulocyte cell in the
integrated control, Janik testified that, "[e]ven if [Ryan's
patent] gave you the exact formula you would have to test it"
but "it doesn't seem like
<span CLASS="page_no" data-cite="665 f 3d 1291" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1291" data-primary-citation="665 F.3d 1269">[*1291]</span> 
it's a huge amount of effort." J.A. 45844:6-14. And, when
asked whether a person skilled in the art would have to conduct
"extraordinary experimentation" rather than "just routine
testing," Janik testified that:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  the reticulocyte analog that was made even looked like
  a real reticulocyte under the microscope . . . You
  can't predict everything, but, you know, if the
  question was would you predict that using animal
  retics would work pretty much as well? The answer
  would be yes, because they both look the same and
  probably act the same to some degree, but would still
  have to be tested with the different instruments and
  understand that.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 45844:21-45845:7. Finally, Streck's expert, Dr. Langley,
testified as follows:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. With regard to the state of the art, as you
  understood it as one of ordinary skill in the art in
  1999, there were a number of complications that you
  would need to overcome in order to take a
  reticulocyte-only control and use it in an integrated
  control; isn't that correct?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. I remember giving that opinion when I was asked to
  analyze the other patent. Yes.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  * * *
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. Dr. Langley, is it correct that I asked you: In
  fact, on the next page of paragraph 39, you lay out a
  number of complications that would need to be overcome
  in order to take a reticulocyte-only control and use
  it in an integrated control, isn't that right? And you
  said yes, correct?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. That's what it says.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. And then I asked you: To overcome those, you would
  have to do a substantial amount of testing, correct?
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. That's &mdash;
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. You said, "I think so, yeah."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. That's what it says.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Q. That's what I thought.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 46013:9-46014:17. According to R &amp; D, this testimony
is evidence of Langley admitting that "there would be a number
of complications to overcome in order to use a true
reticulocyte stand-alone control in an integrated reticulocyte
control." Appellants' Br. 54. Streck accurately responds,
however, that Langley was "discussing the difficulties in
combining any reticulocyte component (true or <span CLASS="page_no" data-cite="2012 bl 5365 p 20" data-cite-type="Bloomberg" data-cite-pageno="20" data-primary-citation="">[***20]</span> analog) into an
integrated control <i>before</i> Ryan disclosed his
invention." Appellee's Br. 45. Langley did not say that making
an integrated control using true reticulocytes would be more
difficult than making it with analogs. Nor did he testify that,
after reading the patents-in-suit, a person of ordinary skill
would have to conduct the same level of experimentation Ryan
already completed to make the claimed invention using
reticulocyte analogs.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The foregoing testimony, when taken in context, establishes
that no undue experimentation would be necessary once the
teachings in the patents-in-suit were known. In light of this
testimony, the district court correctly concluded that there
was no evidence showing that it would make any difference
whether true reticulocytes or reticulocyte analogs were used in
the claimed integrated control. Importantly, there was no
testimony from which a jury could find that using true
reticulocytes would require "undue experimentation."<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a>
Because R &amp; D failed to
<span CLASS="page_no" data-cite="665 f 3d 1292" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1292" data-primary-citation="665 F.3d 1269">[*1292]</span> 
offer any evidence <span CLASS="page_no" data-cite="101 uspq 2d 1240" data-cite-type="ReporterOfDecisions" data-cite-pageno="1240" data-primary-citation="101 U.S.P.Q.2d 1225">[**1240]</span> showing that one skilled in the
art could not follow the patent's teachings to use a true
reticulocyte in the claimed integrated control, a reasonable
jury could not have found the patents invalid for lack of
enablement by clear and convincing evidence.<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a> As such, the
district court did not err in granting Streck's JMOL with
respect to enablement.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  D. Priority and Evidentiary Rulings
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The jury found in favor of Streck on the issue of priority.
R&amp; D filed a renewed motion for JMOL, which the court
denied on grounds that the evidence adduced at trial "supports
the jury's finding that R &amp; D did not prove by clear and
convincing evidence that Dr. Johnson-was the first to invent an
integrated reticulocyte control composition." <i>Denial of</i>
<i>Renewed JMOL Order</i>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 WL 3926059, at *9-10,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 U.S. Dist. LEXIS 104461, at *32.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_386179">[4]</span> In Appeal No. 2011-1045, we affirmed the district court's award
of priority to Streck in the <cite>&sect; 146</cite> action. <i>Streck</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GJH4I003?jcsearch=659%20f%203d%201186&amp;summary=yes#jcite">659 F.3d at 1196</a>. It is undisputed that resolution of priority
in that appeal controls the priority issues here, where R
&amp; D's burden was higher and this court's deference to the jury
verdict is substantial. Specifically, in the <cite>&sect; 146</cite> action,
R&amp; D had to establish priority by a preponderance of the
evidence whereas in this appeal, R &amp; D had to show its
priority defense by clear and convincing evidence. As such, our
decision in <cite>Appeal 2011-1045</cite> that R&amp;D failed to establish
priority by a preponderance of the evidence necessarily means
that R&amp;D could not meet the clear and convincing burden
required in this case. And, because the priority defense here
was decided by a jury, on appeal R &amp; D has to show that the
jury's findings were not supported by substantial evidence. In
addition, as Streck argues, because the <cite>&sect; 146</cite> appeal
involved the same parties, the same evidence, and the same
priority issue presented in this appeal, R &amp; D is barred by
the doctrine of collateral estoppel from challenging this
court's priority determination in <cite>Appeal No. 2011-1045</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the alternative, R&amp; D argues that this court should
overturn the jury verdict and remand for a new trial on
priority because the district court "abused its discretion and
materially prejudiced <span CLASS="page_no" data-cite="2012 bl 5365 p 21" data-cite-type="Bloomberg" data-cite-pageno="21" data-primary-citation="">[***21]</span> R &amp; D's priority case by committing
several errors relating to the presentation of evidence."
Appellants' Br. 63-64. In particular, R&amp; D argues that the
court erred when it: (1) denied R &amp; D's motion <i>in</i>
<i>limine</i> regarding conception and diligence; (2) failed to
control the order of proof by allowing Streck "to preemptively
rebut R &amp; D's case-in-chief on invalidity"; and (3)
submitted a misleading question to the jury on the verdict
form. Each of these arguments relates to priority, which, as
previously discussed, is controlled by this court's prior
decision in the companion appeal. Resolution of that appeal
renders
<span CLASS="page_no" data-cite="665 f 3d 1293" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1293" data-primary-citation="665 F.3d 1269">[*1293]</span> 
R &amp; D's arguments regarding priority moot.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  To the extent R &amp; D's evidentiary challenges can be
construed to relate to any-thing other than priority, we have
considered them and find that they are without merit,
particularly given the level of deference afforded to district
courts with respect to motions <i>in limine</i>, and the
order of proof and presentation of evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                              E. Injunction
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  After the jury trial, Streck moved for a permanent injunction.
The district court applied the four-factor test for injunctive
relief set forth in <i>eBay, Inc. v. MercExchange, LLC</i>,
<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X151TO4003?jcsearch=547%20us%20388&amp;summary=yes#jcite">547 U.S. 388</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X151TO4003?jcsearch=547%20us%20388&amp;summary=yes#jcite">391</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X151TO4003?jcsearch=126%20supreme%20court%201837&amp;summary=yes#jcite">126 S.Ct. 1837</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X151TO4003?jcsearch=164%20l%20ed%202d%20641&amp;summary=yes#jcite">164 L.Ed.2d 641</a> (2006), and
concluded that all four factors favored entry of an injunction.
Specifically, the court ordered that R &amp; D is prohibited
from:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  making, using, offering to sell, selling, or importing
  into the United States, or supplying from the United
  States, or causing to be made, used, offered for sale,
  sold, imported into the United States, or supplied
  from the United States the infringing hematology
  control products presently designated CBC-XE, CBC-4K
  Plus Retics, and CBC-5D Plus Retics, as well as any
  hematology control products that are only colorably
  different therefrom in the context of the in-fringed
  claims, whether individually or in combination with
  other products or as a part of another product, and
  from otherwise infringing the asserted claims of [the
  patents-in-suit] until the expiration of the last to
  expire of the Patents-in-Suit.
<span CLASS="page_no" data-cite="101 uspq 2d 1241" data-cite-type="ReporterOfDecisions" data-cite-pageno="1241" data-primary-citation="101 U.S.P.Q.2d 1225">[**1241]</span> </p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
J.A. 40047 (internal statutory citations omitted). We review
the district court's decision entering an injunction, as well
as the scope of the injunction, for abuse of discretion.
<i>i4i Ltd. P'ship v. Microsoft Corp.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CQR6E003?jcsearch=598%20f%203d%20831&amp;summary=yes#jcite">598 F.3d 831</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1CQR6E003?jcsearch=598%20f%203d%20831&amp;summary=yes#jcite">861</a>
(Fed. Cir. 2010) (citation omitted).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  R &amp; D argues that the district court erroneously entered
the injunction and that the injunction itself is overbroad
because it prohibits R&amp; D "from otherwise infringing the
asserted claims of [the Patents-in-Suit] until the expiration
of the last to expire of the Patents-in-Suit." Appellants' Br.
69. Specifically, R&amp; D asks this court to vacate the
injunction or replace it with one limited to "the adjudicated
CBC-XE, CBC-4K Plus Retics, and CBC-5D Plus Retics products,
and products not more than colorably different therefrom."
<i></i><cite>Id. at 70</cite>. Streck responds that "the injunction
already prohibits exactly what R&amp; D proposes by expressly
listing the three adjudicated products and extending only to
products that are `only colorably different therefrom.'"
Appellee's Br. 64. We agree with Streck.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <span id="headnote_ref_pq2-dec_386180">[5]</span> R&amp; D does not challenge any of the court's underlying
<i>eBay</i> findings. <span CLASS="page_no" data-cite="2012 bl 5365 p 22" data-cite-type="Bloomberg" data-cite-pageno="22" data-primary-citation="">[***22]</span> As such, R &amp; D's sole argument on
appeal relates to overbreadth. After careful consideration, we
find that R &amp; D's argument is without merit, particularly
given the language in the injunction referring to the specific
products at issue in this case. Mere inclusion of the phrase
"from other-wise infringing the asserted claims," when taken in
the context of the entire order and record on which it was
entered, does not render the injunction overbroad. <i>See</i>
<i>Signtech USA Ltd. v. Vutek, Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X36A66?jcsearch=174%20f%203d%201352&amp;summary=yes#jcite">174 F.3d 1352</a>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X36A66?jcsearch=174%20f%203d%201352&amp;summary=yes#jcite">1359</a>
(Fed. Cir. 1999) (holding that, in light of the "detailed record"
on which it was entered, an injunction prohibiting "any further
infringement . . . of the patent" complied with the specificity
requirements set forth in Fed.R.Civ.P. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X144L50003?jcsearch=Fed.%20R.%20Civ.%20P.%2065(d)&amp;summary=yes#jcite">65</a>(d)). Simply put, we
read the injunction to contain the very limitations R&amp; D
now seeks.
<span CLASS="page_no" data-cite="665 f 3d 1294" data-cite-type="PrimaryFederalReporter" data-cite-pageno="1294" data-primary-citation="665 F.3d 1269">[*1294]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
                               CONCLUSION
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  For the foregoing reasons, and because we find that R &amp; D's
remaining arguments are without merit, we affirm the district
court's judgment against R&amp; D and its decision entering a
permanent injunction in favor of Streck.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  <b>AFFIRMED</b>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> <i>Streck, Inc. v. Research &amp; Diagnostic Sys.,</i>
<i>Inc.</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1GJH4I003?jcsearch=659%20f%203d%201186&amp;summary=yes#jcite">659 F.3d 1186</a> (Fed. Cir. 2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Reticulocytes are "anucleate immature red blood cells
containing some ribonucleic acid." <i>Streck, Inc. v. Research</i>
<i>&amp; Diagnostic Sys., Inc.</i>, No. <cite>8:06cv458</cite>,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">2008 BL 253491</a>], 2008 WL 4891132, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X19TN1K003?jcsearch=2008%20BL%20253491&amp;summary=yes#jcite">2008 BL 253491</a>], 2008 U.S. Dist. LEXIS 91865 (D.Neb. Nov. 12, 2008)
("<i>Claim Construction Order</i> ").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> The terms "true reticulocytes" and "natural
reticulocytes" are used interchangeably to refer to naturally
occurring reticulocytes. For consistency, we refer to them as
"true reticulocytes."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The Patent Local Rules for the Northern District of
California were revised in 2008. The versions cited herein were
in effect from January 1, 2001 to February 29, 2008.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> In its summary judgment order, the district court states
that R &amp; D amended its invalidity contentions in March
2007, but R &amp; D admits, and the record reflects, that the
amendment did not occur until March 2008. Appellants' Reply Br.
3; J.A. 43368.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> The misjoinder issue related to whether Dr. John Scholl
was properly listed as an inventor on one of Streck's
patents.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> The district court also dismissed R &amp; D's misjoinder
claim (relating to inventorship) on grounds that R &amp; D
failed to raise that claim in its final invalidity contentions
and that even if it had, R &amp; D failed to provide clear and
convincing evidence that the inventorship was incorrect.
<i>Summary Judgment Order</i>, <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6L77T7J82?jcsearch=658%20f%20supp%202d%20988&amp;summary=yes#jcite">658 F.Supp.2d at 1000</a>.
Misjoinder is not an issue on appeal.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> As noted above, in its December 2006 infringement
contentions, Streck identified fifteen asserted claims. In its
December 2008 correspondence to R &amp; D, Streck reduced the
number of asserted claims to a total of ten (Claims 28-29 of
the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G005000J?jcsearch=usp%206200500&amp;summary=yes#jcite">500 Patent</a>; Claims 1, 4, 5, 6, 8, 9, and 13 of the
&prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a>; and Claim 13 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30P4I3420J?jcsearch=usp%206399388&amp;summary=yes#jcite">388 Patent</a>). In
May 2009, Streck removed Claim 4 of the &prime;<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X30G826320J?jcsearch=usp%206221668&amp;summary=yes#jcite">668 Patent</a> from
the list of asserted claims, thus reducing the number to a
total of nine claims. <i>Streck, Inc. v. Research</i>
<i>&amp; Diagnostic Sys. Inc.</i>, No. <cite>8:06cv458</cite> (D.Neb. Sept. 4,
2009), ECF No. 236-5 at 2.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> The sole count in the PTO Interference recited a
"hematology control composition comprising: (a) a stabilized
reticulocyte component; and (b) a fixed and stabilized white
blood cell component capable of exhibiting a five-part
differential."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> As noted below, R &amp; D's discussion of timing with
respect to the unasserted claims ignores the fact that Streck
served its preliminary infringement contentions, which narrowed
significantly the scope of the asserted claims, only months
after the action was filed.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> R &amp; D's assertion that Streck did not narrow its
asserted claims until 2008 is wrong. Although neither party
cites to the preliminary infringement and invalidity
contentions, a careful examination of the docket clarifies that
the timing described here is, in fact, the correct one.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> The fact that R &amp; D amended its invalidity
contentions in March 2008 and January 2009 does not alone
create a case or controversy.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> In its order denying R &amp; D's renewed motion for JMOL
and motion for a new trial, the district court specifically
found that "Streck presented undisputed evidence that its
invention was properly enabled" and that R&amp; D failed to
show that a person skilled in the art would have to undergo
"undue experimentation" "to create a control composition with
other reticulocyte analogs than those described in the patent."
<i>Denial of Renewed JMOL Order</i>, [<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 WL 3926059, at *11,
[<a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LEG6DJO2?jcsearch=2010%20BL%20229075&amp;summary=yes#jcite">2010 BL 229075</a>], 2010 U.S. Dist. LEXIS 104461, at *36.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> While we believe the evidence clearly supports a finding
of enablement, the standard of review imposed upon us by the
district court's decision to take this fact laden inquiry away
from the jury is an exacting one. Despite careful application
of that standard of review, we ultimately conclude that the
district court's JMOL ruling should be affirmed. <i>See</i>
Fed.R.Civ.P. <a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X144L3U003?jcsearch=frcp%2050(b)&amp;summary=yes#jcite">50</a>(b) advisory committee's note on the 1991
amendments ("[T]he court may often wisely decline to rule on a
motion for judgment as a matter of law made at the close of
evidence, and it is not inappropriate for the moving party to
suggest such a postponement of the ruling until after the
verdict has been rendered.").
</p></div>
<!--BBLS DD 1682407817219-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1GURL4003/history">Direct History (17)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1GURL4003/analysis">Case Analysis (32)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1GURL4003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
31
</span>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/distinguished.png'>
<div class='citation distinguished icon printHide' title='Distinguished'></div>
<a class='citationAnalysisLabel' href='/bcite/X1GURL4003/analysis?analysis=distinguished'>
Distinguished
</a>
<span class='citationNumberLabel'>
1
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Judgment Affirmed</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Medical Devices</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/4e497939ce7d90f53679c7e8161db722/document/X1Q6LF9JBGO2">11-01044 (Fed. Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Civil Procedure</div><div class='facetItemLabel'>Copyright Law</div><div class='facetItemLabel'>Damages &amp; Remedies</div><div class='facetItemLabel'>Patent Law</div><div class='facetItemLabel'>Trademark Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/4e497939ce7d90f53679c7e8161db722/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "4e497939ce7d90f53679c7e8161db722";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYd94091&previousPageId=&previousActivityInstanceId=ENTITY88df94&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:28:10-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1GURL4003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITY88df94&previousPageId=&previousActivityInstanceId=ENTITY36d97a&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T00:28:06-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1GURL4003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1GURL4003";
$('#page_loader').show().spin();
JUDGE_IDS=["1850676","3057465","4283465"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
